On 28th August 2023, HiFiBiO Therapeutics, a TIBS-invested company, was named as one of 2023’s “Fierce 15” biotechnology companies by Fierce Biotech.

This annual special report features the most innovative and promising early-stage biotechnology companies in the industry. In curating this list, Fierce Biotech has considered a diverse range of factors, including the robustness of the companies’ technology, partnerships, venture support and competitive positioning within the market.

The Fierce 15 recognition reflects HiFiBiO’s passionate dedication to patients with unmet medical needs. And it has further highlighted the company’s unique Drug Intelligence Science (DIS®) approach to enhance the probability of success of immunotherapy from targets to drugs to patients. The company is differentiated by its pioneering DIS® approach which combines a proprietary microfluidic single-cell platform with advanced AI/ML-based (Artificial Intelligence/Machine Learning) data analytics to gain unprecedented insights into human disease biology. HiFiBiO has used this rapid development process to churn out eight clinical candidates, four of which are currently in phase 1 trials, two slated for an IND filing in 2024 and two others handed over to FibroGen. The company has also inked a clinical supply agreement for Novartis’ anti-PD-1 tislelizumab, now being tested in a phase 1 trial alongside HiFiBiO’s BTLA inhibitor.

With more than $180M in financing from world-class investors and an experienced top-tier scientific and clinical team, HiFiBiO is well-positioned to deliver effective therapeutic solutions for patients globally. TIBS invested in HiFiBiO in 2021.

More details, please find at https://www.fiercebiotech.com/special-reports/